Objectives: The objective of this prospective study was to analyze the effect of vaginal micronized progesterone (VMP) daily administrated in women with recurrent pregnancy loss, recurrent miscarriage, and/or preterm birth on neonatal outcomes.
INTROduCTION
The growth and development of the conceptus (embryo/ fetus), and of the extra-embryonic membranes in mammals requires progesterone and placental hormones. These hormones regulate differentiation and function of endometrial stromal cells, uterine receptivity for blastocyst implantation, pregnancy recognition signaling and interactions between the maternal and fetal DNA.
1 Additionally, these hormones are involved in the embryo protection from malformations and rejection, 2,3 its growth, development, and prevention of preterm birth.
In the last 40 to 50 years, progestins and progesterone derivatives have been used during reproductive age for support of luteal phase when luteal phase defect or inadequate corpus luteum were present. Prostins and progesterones were also used for spontaneous pregnancy achievement or in vitro fertilization treatment; 4, 5 prevention of miscarriages, 6 preterm labor 7 and recurrent pregnancy loss. 8 Progesterone is used as a support for pregnancy in women with short cervix, [9] [10] [11] and as monotherapy for primary prevention of preterm birth, 12, 13 with a good cost-effective ratio.
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PATIeNTS ANd MeThOdS
The objective of this prospective study was to analyze the effect of daily administration of 200 mg vaginal micronized progesterone (VMP) from preconception to complete 36 weeks of gestation in women with recurrent pregnancy loss, recurrent miscarriage, and/or preterm birth on neonatal outcome. This was a prospective controlled study conducted from January 2007 to December 2011 with the following inclusion criteria; pregnant women with a history of at least two miscarriages or at least a preterm birth at 26 to 37 weeks, and cervical length at enrollment ≥20 mm. Exclusion criteria were as follows: pregnant women with major uterine malformations, infection with toxoplasma, listeria, cytomegalovirus or syphilis; chronic diseases (e.g. insulin treated diabetes mellitus, hypertension, treatment with
DSJUOG
Statistical Analysis
The treatment groups were compared using the student t-test and ANOVA procedure. A p-value <0.01 was considered statistically significant.
ReSuLTS
Seven hundred and forty treated patients and 660 controls with similar mean age were included in this analysis (Table 1) . Six hundred and forty-eight (84.2%) of the treated women and 390 (60.7%) of the women in the control group had a time between study enrollment and conception of <6 months. One hundred and seventy (21.9%) women from the treatment group and 154 (23.4%) from the control group presented a miscarriage during the first 12 weeks of gestation. Between 16 and 24 weeks of gestation women from the treatment group reported statistically significant fewer miscarriages than the women from the control group: 70 (7.2%) vs 60 (9.3%); p < 0.001. The mean gestational age at delivery was 38.27 ± 1.61 weeks in the treatment group and 35.09 ± 3.05 weeks in the control group, p < 0.001. Ten (1.3%) women from the treatment group and 29 (4.8%) from the control group delivered between 24 and 28 weeks of gestation; 34 (5.3%) women from the treatment group and 250 (39%) from the control group delivered between 29 and 34 weeks of gestation; 386 (93.4%) women from the treatment group and 167 (56.2%) women from the control group delivered ≥35 weeks. The gestational age at delivery according to the cervical length measured at 16 to 23 weeks and 6 days is presented in Table 2 .
Newborns from VPM treated mothers had a significantly higher birth weight than newborns from untreated mothers unfractioned or low molecular weight heparins, coagulopathies or platelet disorders); previous pregnancies with chromosomal abnormalities (numerical, aneuploidies, or structural chromosomal defects); previous pregnancy with duration over 42 weeks with stillborn fetus. All treated patients signed an informed consent before enrollment and before conception.
There were two study groups: the treatment group and the control group. In the treatment group patients received 200 mg/day VMP (14 days/month, during the luteal phase) from preconception until completed 36 weeks of gestation. Women from the control group did not receive VPM treatment. When considered necessary, the treating physician offered a nonspecific muscle-relaxant mixture.
Ultrasonographic examination was performed at 16 to 23 weeks and 6 days of gestation for gestational age confirmation, assessment of cervical length and screening for congenital malformations. This examination was repeated at 32 to 34 weeks of gestation for assessment of fetal development and maturation.
The primary outcomes were time until conception (<6 months, >6 months), evaluation of gestational age (GA) at miscarriage, GA at delivery, GA at birth according to the cervical length at 16 to 23 weeks and 6 days, birth weight, Apgar scores, the presence of congenital malformations and neonatal morbidity including severe respiratory distress syndrome, bronchopulmonary dysplasia, intraventricular hemorrhage and necrotizing enterocolitis. The secondary outcomes were the frequency of stillbirths, fetal deaths before discharge, oxygen supplementation, mechanical ventilation and the length of stay at Neonatal Intensive Care Unit. (p = 0.022). Number of newborns from treated mothers with Apgar score <7 at 5 minutes was significantly lower that the number of newborns from untreated mothers (p > 0.001) ( Table 3 ). The frequency of stillbirths and the need for oxygen supplementation and mechanical ventilation were lower in the newborns from treated mother compared with those from untreated mothers ( Table 4 ). The frequency of fetal death before discharge was similar in the two groups: 1.08 and 1.5% in the newborns from treated and untreated mothers respectively.
dISCuSSION
As many eastern European countries, Romania has experienced a decline of the population with a negative population growth rate in 2007. The early neonatal mortality remained high compared with mortality rates at European level (6.09 vs 3.75/1,000 live births in Europe in 2005) but the infant mortality rate declined from 17.3 in 2002 to 9.2 deaths/1,000 live births in 2010. 15 In this context, the healthcare professionals have the very important task of improving pregnancy outcomes.
The use of progesterone derivatives and progestins for reproduction has been discussed in the last 40 to 50 years. Currently, two types of progesterone formulations considered safe are available: natural progesterone with either oral or vaginal administration, and a semi-synthetic progesterone derivative only with oral administration.
Vaginal route is associated with a higher bioavailability of progesterone in the uterus (10 fold higher than after the oral administration), and minimal systemic undesirable effects. [16] [17] [18] [19] This higher bioavailability can be explained by the first uterine pass effect: direct diffusion through tissue, intracervical aspiration, absorption into the venous or lymphatic circulatory systems, and countercurrent vascular exchange with diffusion from uterovaginal veins and lymph vessels to arteries.
In our study, maternal age in treated patients was higher than in controls (27.97 ± 4.74 vs 27.33 ± 4.54; p = 0.43).
DSJUOG
It was shown that the level of proinflammatory cytokines, reactive oxygen species, steroids and inducible nitric oxide synthase linked to apoptosis of corpus luteum increase with age. 20 These cytokines and hormones induce a decrease of progesterone biosynthesis in mid and late luteal cells. 20 Preconception progesterone supplementation increases the number of natural killer (uNK) cells CD56 bright CD16 dim in the pre-decidualized endometrium during luteal phase. 21 These uNK, that are β-hCG dependent from early moments of pregnancy, are phenotypically distinct from circulating peripheral CD56 dim CD16
bright and their number increases during pregnancy, contributing to a normal pregnancy and fetal development. 22 Additionally, progesterone increases local production of Th2 and/or Leukemia Inhibiting Factor (LIF) cytokines which may contribute to the maintenance of pregnancy. The defective decidual production of LIF, M-CSF, Il -4, IL-10 and/or Th2 cytokines may be associated with unexplained recurrent abortions. [23] [24] [25] Preconception progesterone supplementation modulates the contractility of fallopian tubes and myometrium for gamete/embryo transport throughout the uterotubal cavities and successful embryo implantation in spontaneous and/or assisted reproduction [26] [27] [28] [29] [30] [31] and maintains the viability of the decidua. 32 Together with estrogens it decreases the vascular resistance in the uterine circulation and increases the rates of embryo implantation. These effects are mediated through its action on the endometrial stroma cells and on different cytokine profiles secreted in response to the paternal MHC histocompatibility antigens (the uterus is an immuneprivileged site during pregnancy). Taking into account the mechanism underlying human parturition initiation 'progesterone functional withdrawal' [33] [34] [35] [36] and because progestins/progesterone derivatives suppress Thrombin-and Il-1(beta)-induced interleukin 11 activities related to preterm delivery, the proges terone supplementation for prevention of preterm birth, 5 abruptio placentae and chorioamnionitis 37 is widely accepted.
Progesterone supplementation can be administered in different doses (from 90 mg/day to 200 mg/day [38] [39] [40] ), according to medical history [40] [41] [42] and treatment duration. [40] [41] [42] [43] We believe that a pregnancy should continue at least up to 37 complete weeks of gestation, because each week reduces neonatal risk. It was shown that VMP administration from preconception up to complete 36 weeks of gestation reduced the delivery rates before 37 weeks (p < 0.01).
Recently the cervical length has been used as an parameter indicating the risk for late miscarriage or early preterm birth. [9] [10] [11] 44 We analyzed the VMP effect on pregnancy prolongation according to cervical length (below 10 mm or more) at 16 to 24 weeks gestation and we showed that in cases with known risk of recurrent preterm delivery progesterone supple mentation early during the pregnancy, before the cervix becomes shorter, decreases the frequency of delivery before 36 weeks of gestation. Our results are in line with those previously reported.
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A meta-analysis of 2611 randomized clinical trials 45 in asymptomatic women with a sonographic short cervix in the mid trimester of singleton and twin pregnancies, showed the efficacy and safety of vaginal progesterone for the prevention of preterm birth.
CONCLuSION
Vaginal micronized progesterone administered from preconception to 36 weeks of gestation in women with history of pregnancy loss and shortened cervix the frequency of miscarriages and preterm births and increases the gestational age at delivery. Additionally in newborns, its administration was associated with higher birth weight, lower number of cases with low umbilical cord pH at birth when Apgar score was <7 at 5 minutes and with a reduction of neonatal morbidity and mortality.
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